Guillaume M Hautbergue1,2,3, John D Cleary4,5,6, Shu Guo4,5,6, Laura P W Ranum4,5,6,7,8. 1. Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield. 2. Neuroscience Institute. 3. Healthy Lifespan Institute (HELSI), University of Sheffield, Western Bank, Sheffield, UK. 4. Center for NeuroGenetics. 5. Department of Molecular Genetics and Microbiology, College of Medicine. 6. Genetics Institute. 7. McKnight Brain Institute. 8. Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.
Abstract
PURPOSE OF REVIEW: An intronic G4C2 expansion mutation in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). Although there are currently no treatments for this insidious, fatal disease, intense research has led to promising therapeutic strategies, which will be discussed here. RECENT FINDINGS: Therapeutic strategies for C9-ALS/FTD have primarily focused on reducing the toxic effects of mutant expansion RNAs or the dipeptide repeat proteins (DPRs). The pathogenic effects of G4C2 expansion transcripts have been targeted using approaches aimed at promoting their degradation, inhibiting nuclear export or silencing transcription. Other promising strategies include immunotherapy to reduce the DPRs themselves, reducing RAN translation, removing the repeats using DNA or RNA editing and manipulation of downstream disease-altered stress granule pathways. Finally, understanding the molecular triggers that lead to pheno-conversion may lead to opportunities that can delay symptomatic disease onset. SUMMARY: A large body of evidence implicates RAN-translated DPRs as a main driver of C9-ALS/FTD. Promising therapeutic strategies for these devastating diseases are being rapidly developed with several approaches already in or approaching clinical trials.
PURPOSE OF REVIEW: An intronic G4C2 expansion mutation in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). Although there are currently no treatments for this insidious, fatal disease, intense research has led to promising therapeutic strategies, which will be discussed here. RECENT FINDINGS: Therapeutic strategies for C9-ALS/FTD have primarily focused on reducing the toxic effects of mutant expansion RNAs or the dipeptide repeat proteins (DPRs). The pathogenic effects of G4C2 expansion transcripts have been targeted using approaches aimed at promoting their degradation, inhibiting nuclear export or silencing transcription. Other promising strategies include immunotherapy to reduce the DPRs themselves, reducing RAN translation, removing the repeats using DNA or RNA editing and manipulation of downstream disease-altered stress granule pathways. Finally, understanding the molecular triggers that lead to pheno-conversion may lead to opportunities that can delay symptomatic disease onset. SUMMARY: A large body of evidence implicates RAN-translated DPRs as a main driver of C9-ALS/FTD. Promising therapeutic strategies for these devastating diseases are being rapidly developed with several approaches already in or approaching clinical trials.
Authors: Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo Journal: Cell Date: 2017-08-10 Impact factor: 41.582
Authors: Peter E A Ash; Kevin F Bieniek; Tania F Gendron; Thomas Caulfield; Wen-Lang Lin; Mariely Dejesus-Hernandez; Marka M van Blitterswijk; Karen Jansen-West; Joseph W Paul; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli Journal: Neuron Date: 2013-02-12 Impact factor: 17.173
Authors: Brian D Freibaum; Yubing Lu; Rodrigo Lopez-Gonzalez; Nam Chul Kim; Sandra Almeida; Kyung-Ha Lee; Nisha Badders; Marc Valentine; Bruce L Miller; Philip C Wong; Leonard Petrucelli; Hong Joo Kim; Fen-Biao Gao; J Paul Taylor Journal: Nature Date: 2015-08-26 Impact factor: 49.962
Authors: Qihui Zhou; Nikola Mareljic; Meike Michaelsen; Samira Parhizkar; Steffanie Heindl; Brigitte Nuscher; Daniel Farny; Mareike Czuppa; Carina Schludi; Alexander Graf; Stefan Krebs; Helmut Blum; Regina Feederle; Stefan Roth; Christian Haass; Thomas Arzberger; Arthur Liesz; Dieter Edbauer Journal: EMBO Mol Med Date: 2019-12-20 Impact factor: 12.137
Authors: Guillaume M Hautbergue; Lydia M Castelli; Laura Ferraiuolo; Alvaro Sanchez-Martinez; Johnathan Cooper-Knock; Adrian Higginbottom; Ya-Hui Lin; Claudia S Bauer; Jennifer E Dodd; Monika A Myszczynska; Sarah M Alam; Pierre Garneret; Jayanth S Chandran; Evangelia Karyka; Matthew J Stopford; Emma F Smith; Janine Kirby; Kathrin Meyer; Brian K Kaspar; Adrian M Isaacs; Sherif F El-Khamisy; Kurt J De Vos; Ke Ning; Mimoun Azzouz; Alexander J Whitworth; Pamela J Shaw Journal: Nat Commun Date: 2017-07-05 Impact factor: 14.919
Authors: Feilin Liu; Dmytro Morderer; Melissa C Wren; Sara A Vettleson-Trutza; Yanzhe Wang; Benjamin E Rabichow; Michelle R Salemi; Brett S Phinney; Björn Oskarsson; Dennis W Dickson; Wilfried Rossoll Journal: Acta Neuropathol Commun Date: 2022-02-14 Impact factor: 7.801